Cowen initiated coverage on shares of Vir Biotechnology (NYSE:VIR) in a research note issued to investors on Tuesday, The Fly reports. The firm issued an outperform rating on the stock.
Shares of NYSE VIR traded down $0.70 during mid-day trading on Tuesday, reaching $13.83. 169,208 shares of the company were exchanged, compared to its average volume of 214,875. Vir Biotechnology has a twelve month low of $13.39 and a twelve month high of $16.50.
In other Vir Biotechnology news, insider Abu Dhabi Investment Authority acquired 1,000,000 shares of the company’s stock in a transaction on Wednesday, October 16th. The stock was acquired at an average price of $14.41 per share, for a total transaction of $14,410,000.00. Also, major shareholder Endurance (Cayman) Ltd Svf acquired 950,000 shares of the company’s stock in a transaction on Wednesday, October 16th. The stock was acquired at an average price of $14.22 per share, with a total value of $13,509,000.00.
Vir Biotechnology Company Profile
Vir Biotechnology, Inc, a clinical-stage immunology company, develops therapeutic products for the treatment and prevention of serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus, and VIR-2020 for the prevention of tuberculosis.
Further Reading: Investing strategies using the yield curve